Neoplasm Metastases
Conditions
Keywords
brain metastases, Gamma Knife, Radiosurgery, Quality of Life
Brief summary
The aim of the study is to assess prospectively the impact of radiosurgery on the quality of life in patients with brain metastases.
Detailed description
The patients who meet the selection criteria and who have accepted to participate at the study will answer different questionnaires of the study before radiosurgery and at 3, 6, 9 and 12 months after the treatment of brain metastases. Baseline examinations will be done before receiving the treatment during the hospitalisation for the Gamma Knife treatment, and then they will be repeated at the evaluation visits which are classically done every 3 months. MRI's will also be performed every 3 months. In this way, no additional travel or MRI will be carried out as part of the study.
Interventions
OTHERquestionnaire administration
Within 15 days before radiosurgery and then at 3, 6, 9, 12 months after radiosurgery, the patients who have accepted to participate will have to complete these questionnaires : QLQC30, BN20, IADL, HADS, MoCa, Edmonton Symptom Assessment Scale
Sponsors
Centre Oscar Lambret
Centre Hospitalier Universitaire de Besancon
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient with newly diagnosed brain metastases * Patient with cancer regardless of the type of primary cancer, with anatomopathological proof * At least, one measurable lesion ≥ 10 mm on the MRI T1 gadolinium sequences * Number of brain metastases lower or equal to 5 * Indication of radiosurgery treatment * Age ≥ 18 years old * ECOG-PS 0-2 * Expected survival \> 3 months * Ability to complete self-administered questionnaires. If the patient has a motor disability (hemibody deficit) that does not allow to complete himself the questionnaires, these will be read by a CRA of the Neurosurgery department who will outline the questions without making any comment. * A non-opposition form must have been completed by the patient
Exclusion criteria
* Previous cancer (\< 5 years) except of carcinoma of cervix uteri, basal cell or squamous cell skin carcinoma adequately treated * Previous brain radiotherapy * Neurological pathology with cognitive disorders existing before the study * Having a contraindication for MRI * Associated leptomeningeal disease * Patients having another severe or uncontrolled pathology which could compromise the participation at the study (such as infection, cardiovascular, digestive, renal or pulmonary disease) * Pregnant or breastfeeding woman. The women must not breastfeed for at least 6 months * Impossibility to submit to the medical examinations of the study due to geographic, social or mental reasons
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Impact at 6 months of the radiosurgery based on the evaluation of 4 criteria of the QLQ C30 questionnaire | 6 months | The 4 criteria are the perceived overall state, health, physical functioning, cognitive functioning and tiredness |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Comparison of the scores obtained on the scales, questionnaires and Performance status at baseline and every 3 months (until 12 months) after Gamma Knife treatment | 1 year | QLQ C30, BN20 (quality of life), IADL (autonomy), HADS (anxiety-depression), MoCA (cognition), ESAS (quality of life), Performance status (OMS) |
| Comparison of the scores obtained on the scales and questionnaires according to the type of primary cancer at baseline and every 3 months (until 12 months) after Gamma Knife treatment | 1 year | QLQ C30, BN20 (quality of life), IADL (autonomy), HADS (anxiety-depression), MoCA (cognition) |
| Comparison of the scores obtained on different scales according to the type of associated treatments at baseline and every 3 months (until 12 months) after Gamma Knife treatment | 1 year | The type of associated treatments are: chemotherapy, targeted therapy, corticoids, anti-epileptics, psychotropic drugs. The different scales are QLQ C30, BN20 (quality of life), IADL (autonomy), HADS (anxiety-depression), ESAS (quality of life) and MoCA (cognition) |
| Correlation between the scores obtained on the different scales at the baseline and the progression-free survival / overall survival | 1 year | — |
| Correlation between the scores obtained on the scales QLQ C30, BN20 (quality of life), IADL (autonomy), HADS (anxiety-depression), MoCA (cognition), ESAS (quality of life) at baseline and those obtained at 3, 6, 9, 12 months | 1 year | — |
| Correlation between the scores obtained on the scales during the study and the clinical neurological response at baseline and every 3 monts until 12 months after Gamma Knife treatment | 1 year | The correlation will take into account the evolution of the systemic disease and the volumetric tumor response. Volumetric tumor responses will be calculated on the MRI's |
Countries
France
Contacts
PRINCIPAL_INVESTIGATOREmilie Le Rhun, MD
Centre Oscar Lambret
STUDY_DIRECTORFranck Bonnetain, MD
CHRU de Besançon
Outcome results
None listed